Open an account

Palvella Therapeutics

PVLA · NASDAQ

$123.92+$0.96 (+0.78%)TodayMarket closed ·
Prev close $122.96

About PVLA

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 29 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Employees
29
Headquarters
Wayne, Pennsylvania
Listed
Dec 18, 2014
Sector
Health Care
Industry
Biotechnology
Website
palvellatx.com

PVLA key statistics

Market cap
1.79B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
230.16K
Volume
267.69K
Open price
$123.30
High today
$131.03
Low today
$122.54
52 Week high
$161.38
52 Week low
$68.96

Palvella Therapeutics (PVLA) at a glance

Palvella Therapeutics (PVLA) last traded at $123.92, with a market cap of 1.79B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $122.54 and $131.03. The current price is 1.1% above the day's low and 5.4% below its high.

Volume so far is 267.69K shares, in line with the average of 230.16K shares a day.

Over the past year Palvella Therapeutics has ranged from $68.96 to $161.38, and now sits 59% of the way up that range.

Palvella Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$1.52 per share against an estimate of -$1.18.

The average analyst price target is $234.47, 89.2% above the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 15 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 18 analystsAvg $234.47
Low
$207.05
Now
$123.92
High
$283.50

PVLA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 87.9% on average.

  1. Q3 FY23: reported $3.20 per share against an estimate of -$8.98
  2. Q4 FY24: reported -$2.72 per share against an estimate of -$0.6579
  3. Q1 FY25: reported -$0.74 per share against an estimate of -$1.24
  4. Q2 FY25: reported -$0.86 per share against an estimate of -$0.7556
  5. Q3 FY25: reported -$1.03 per share against an estimate of -$0.8551
  6. Q4 FY25: reported -$1.07 per share against an estimate of -$0.9295
  7. Q1 FY26: reported -$1.20 per share against an estimate of -$0.9508
  8. Q2 FY26: reported -$1.52 per share against an estimate of -$1.18

PVLA news

  • Press releaseBusiness Wire

    Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

  • Press releaseGlobe Newswire

    Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Avi Kapoor

    Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday

  • Press releasePRNewswire

    ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors

  • Avi Kapoor

    Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as Palvella Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.